2003; baxter - Supplements - Haematologica

More documents

Recommendations

Info

110L. Nemes et al.References1. Green D, Lechner K. A survey of 215 non-hemophilicpatients with inhibitors to factor VIII. Thromb Haemost1981; 45:200-3.2. Lottenberg R, Kentro TB, Kitchens CS. Acquired hemophilia:A natural history study of 16 patients with factorVII inhibitor receiving little or no therapy. Arch InternMed 1987; 147:1077-81.3. Kessler CM, Nemes L. Acquired inhibitors to factor VIII.In: Rodriguez-Merchan EC, Lee CA eds. Inhibitors inpatients with haemophilia. Blackwell, 2002.4. Morrison AE, Ludlam CA, Kessler CM. Use of porcinefactor VIII in the treatment of patients with acquiredhemophilia. Blood 1993; 81:1513-20.5. Hay CR, Colvin BT, Ludlam CA, Hill FGH, Preston FE.Recommendations for the treatment of factor VIIIinhibitors: from the UK Haemophilia Centre Directors’Organisation Inhibitor Working Party. Blood Coagul Fibrinolysis1996; 7:134-8.6. Rubinger M, Rivard GM, Teitel J, Walker IL. Suggestionsfor the management of factor VIII inhibitors. Haemophilia2000; Suppl 1 6:52S-9S.7. Morrison AE, Ludlam CA. Acquired haemophilia and itsmanagement. Br J Haematol 1995; 89:231-6.8. Green D, Rademaker AW, Briet E. A prospective, randomizedtrial of prednisone and cyclophosohamid in thetreatment of patients with factor VIII autoantibodies.Thromb Haemost 1993; 70:753-7.9. Shaffer LG, Phillips MD. Successful treatment of acquiredhemophilia with oral immunosuppressive therapy. AnnIntern Med 1997; 127:206-9.10. Cohen AJ, Kessler CM. Acquired inhibitors. In: Lee CA,editor. Haemophilia. Bailliéres Clin Haematol 1996; 9:331-54.11. Brackmann HH, Gormse J. Massive factor-VIII infusionin haemophiliac with factor-VIII inhibitor, high responder.Lancet 1977; 2:933.12. Nilsson IM, Berntorp E, Zettervall O. Induction ofimmune tolerance in patients with hemophilia and antibodiesto factor VIII by combined treatment with intravenousIgG, cyclophosphamide, and factor VIII. N Engl JMed 1988; 318:947-50.13. SchroederJO, Euler HH, Loffler H. Synchronization ofplasmapheresis and pulse cyclophosphamid in severe systemiclupus erythematosus. Ann Intern Med 1987; 107:344-6.14. Lupus Plasmapheresis Study Group. Plasmapheresis andsubsequent pulse cyclophosphamid versus pulse cyclophosphamidalone in severe lupus: design of the LPSG trial.J Clin Apheresis 1991; 6:40-7.15. Jarreusse B, Blinchet P, Gayrand M. Synchronization ofplasma exchanges and cyclophosphamide in severe systemicdiseases. Presse Med 1993; 22:293-8.16. Green D. Suppression of an antibody to factor VIII by acombination of factor VIII and cyclophosphamide. Blood1971; 37:318-7.17. Lian ELY, Larcada AF, Chiu AYZ. Combination immunosuppressivetherapy after factor VIII infusion for acquiredfactor VIII inhibitor. Ann Intern Med 1989; 110:774-8.18. Bucalossi A, Marotta G, De Regis F, Galieni P, DispensaE. A case report of acquired idiopathic hemophilia successfullytreated with immunosuppressive drugs and factorVIII concentrates. Clin Appl Thromb/Hemost 1996;2: 222-3.19. Durig J, de Wit M, Fiedler W, Marx G, Hossfeld DK. ImmunsuppressiveBehandlung einer spontanen HemmkörperhämophilieA mit Cyclophoshamid, Vincristin undPrednison nach vorangegangener Faktor-VIII-Stimulation.Schweiz Med Wochenschr 1996; 126: 20026-31.20. Nemes L, Pitlik E. New protocol for immune toleranceinduction in acquired hemophilia. Haematologica 2000;Suppl 10: 85:64S-8S.21. Lindren A, Wadenvik H, Tarkowski A, Tengborn L. Doesperoral administration of factor VIII induce oral tolerancein patients with acquired haemophilia A? ThrombHaemost 2000; 83:632-3.22. Kessler CM. Acquired factor VIII autoantibody inhibitors:current concepts and potential therapeutic strategies forthe future. Haematologica 2000; Suppl 10: 85:57-63.haematologica vol. 88(supplement n. 12):september 2003
[Gene Therapy]review paperThe host immune response andrisk of inhibitor developmentfollowing adenoviral genetherapy for hemophiliahaematologica 2003; 88(suppl. n. 12):111-114http://www.haematologica.org/free/immunotolerance2001.pdfDAVID LILLICRAPDepartment of Pathology, Richardson LaboratoryQueen’s University, Kingston, Ontario, CanadaBackground and current status ofhemophilia gene therapy trialsHemophilia remains a leading candidate diseasefor the successful application of somatic cellgene therapy. Indicative of this potential, thepast year has witnessed the completion of threephase I/II human clinical trials. Two of thesestudies have involved the delivery of a factor VIIItransgene by either the systemic administrationof a replication defective onco-retrovirus 1 or byex vivo delivery via electroporation to autologousfibroblasts. 2 The third study has involved deliveryof a factor IX transgene through intramuscularinjection of a recombinant serotype 2 Adeno-Associatedviral (AAV) vector. 3 None of thesestudies was associated with any adverse eventsand all three studies documented evidence ofintermittent, transient, low levels of expressionof the transgene product. No evidence ofinhibitor development has been seen in any ofthe twenty seven patients treated in these studies.Following the completion of these initialstudies, two new phase I/II trials have now beenstarted, the first involving hepatic delivery of afactor IX transgene by a serotype 2 AAV vectorand the second a gutless (minimal) adenovirusdelivering factor VIII. These two trials are still inthe very early stages of patient recruitment butboth trials have experienced temporary stoppagesdue to detection of vector in the semen of thefirst two patients in the AAV trial (no vectorfound in sperm) and transient thrombocytopeniain the first patient treated in the adenovirustrial.The objective of this report is to summarizeinformation pertaining to the nature of the hostimmune response associated with the use ofrecombinant adenoviral vectors for hemophiliaCorrespondence: David Lillicrap, Department of PathologyRichardson Laboratory, Queen’s University Kingston, OntarioCanada K7L 3N6. Phone: international +1.613.5481304.Fax: international +1.613.5481356E-mail: lillicrap@cliff.path.queensu.cagene therapy. This discussion also highlights thedifferences in the immune presentation of clottingproteins in the context of gene therapy comparedto routine protein infusion therapy (Figure1).Introduction to adenoviral gene therapyReplication incompetent adenoviruses havenow been used as gene therapy vectors for severalyears. They have a number of important advantagesfor this purpose, the most critical of whichare their ability to very efficiently transduce bothdividing and non-dividing host cells, their capacityfor packaging large transgene cassettes andfinally, the relative ease with which high titers ofthe vector can be produced. 4 All of these featurescontinue to make adenovirus an attractive candidatefor hemophilia gene therapy.However, a significant, ongoing concern associatedwith the delivery of adenoviral vectors isthe nature and magnitude of the host immuneresponse. 5-7 There is ample evidence to indicatethat this response involves early, innate reactivityfollowing within hours of vector delivery anda later, acquired, response involving both cellmediatedand humoral elements of the hostimmune system (Figure 2). The further discussionof these responses requires the separate considerationof so-called early generation vectors inwhich a limited number of early viral genes aredeleted from the vector (ie. E1+E2/E3/E4) andthe most recently generated helper-dependent or“gutless” vectors (also know as minimal or highcapacity vectors). 8,9The host innate immune response toadenoviral gene deliveryThe early, innate immune response to adenoviralgene delivery appears to be against componentsof the viral capsid. While adenovirus isan extremely efficient transducing agent formany different cell types, it is clear that viralentry is accompanied by significant cellular perturbation.Indeed, in preliminary studies of thepatterns of gene expression following adenoviralhaematologica vol. 88(supplement n. 12):september 2003
Page 2 and 3:
haematologicahinformation for autho
Page 4 and 5:
haematologicahImmunobiology of Tole
Page 6 and 7:
[Molecular Genetics]review paperGen
Page 8 and 9:
[Molecular Genetics]review paperGen
Page 10:
6R.C.R. LjungTable 2. Int database
Page 17 and 18:
IV International Workshop on Immune
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
[Round Table on Immune Tolerance Tr
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
[Round Table on Immune Tolerance Tr
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
[Immunobiology of Tolerance Inducti
Page 61 and 62:
Page 63 and 64: IV International Workshop on Immune
Page 73 and 74: [New Aspects in Treatment of Hemoph
Page 97 and 98: [Acquired Inhibitors in Non-Hemophi
Page 113: IV International Workshop on Immune
Page 119 and 120: [Gene Therapy]review paperGene ther
Page 131 and 132: Index of authorsAhmad, R.U., 56Albe
show all

2003; baxter - Supplements - Haematologica

Create successful ePaper yourself

Delete template?

Save as template?